High TMB Predicts Immunotherapy Benefit
- PMID: 29661758
- DOI: 10.1158/2159-8290.CD-NB2018-048
High TMB Predicts Immunotherapy Benefit
Abstract
The first data from the phase III CheckMate-227 trial of ipilimumab plus nivolumab for the treatment of non-small cell lung cancer suggests that the two drugs boost progression-free survival in patients with a high tumor mutation burden. After 1 year, progression-free survival was 43% for patients treated with the checkpoint inhibitor combination, compared with 13% for patients treated with chemotherapy.
©2018 American Association for Cancer Research.
Comment on
-
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16. N Engl J Med. 2018. PMID: 29658845 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
